Recombinant Mouse Protein C19orf12 homolog

What is C19orf12 protein and what is its cellular role?

C19orf12 is a 17 kDa membrane-associated protein originally thought to be exclusively mitochondrial. Research has revealed it is also present in the Endoplasmic Reticulum (ER) and Mitochondria Associated Membrane (MAM) regions . The protein belongs to the clan of glycine zipper-containing membrane domains and likely plays multiple roles in cellular function .

Current evidence suggests C19orf12 may be involved in:

• Lipid metabolism regulation

• Response to oxidative stress conditions

• Possible regulation of autophagy processes

• Potential interaction with magnesium transporters, as its structure contains domains homologous to the N-terminal regulatory domain of bacterial MgtE transporters

What are the key structural features of C19orf12 protein?

C19orf12 protein contains several important structural features:

• Transmembrane regions with glycine zipper motifs: The protein contains glycine-zipper motifs (generally GxxxGxxxG) in its transmembrane regions. These motifs are crucial for:

  • Membrane helix packing

  • Potential homo-dimerization

  • Proper membrane localization

• Soluble regulatory domain: The protein contains a domain homologous to the N-terminal regulatory domain of bacterial MgtE transporters, suggesting a potential regulatory role for magnesium transport .

• Dual isoforms: In humans, the gene codes for two protein isoforms originating from two alternative first exons .

• Highly conserved structure: The protein sequence shows strong evolutionary conservation, particularly in the glycine residues of the transmembrane zipper motif .

How is recombinant mouse C19orf12 protein produced for research purposes?

The recombinant full-length mouse C19orf12 homolog protein can be produced using the following methodology:

• Expression system: The protein is commonly expressed in E. coli bacterial systems .

• Fusion tags: An N-terminal His-tag is typically added to facilitate purification .

• Protein length: The full-length protein (1-141 amino acids) is used to maintain complete structural integrity .

• Purification: Affinity chromatography using Ni-NTA agarose beads is an effective method for purifying the His-tagged protein .

For antibody production, the purified recombinant protein can be used for rabbit immunization to generate polyclonal antibodies .

What are the optimal storage and handling conditions for recombinant C19orf12 protein?

For optimal stability and activity, recombinant C19orf12 protein should be handled according to these guidelines:

• Storage temperature: Store at -20°C/-80°C upon receipt .

• Physical form: The protein is typically supplied as a lyophilized powder .

• Reconstitution: Reconstitute in deionized sterile water to a concentration of 0.1-1.0 mg/mL .

• Stabilization: Add glycerol to a final concentration of 5-50% (optimally 50%) after reconstitution .

• Aliquoting: Create single-use aliquots to avoid repeated freeze-thaw cycles .

• Working storage: Working aliquots can be stored at 4°C for up to one week .

• Buffer composition: The protein is typically stored in Tris/PBS-based buffer with 6% Trehalose, pH 8.0 .

How can researchers accurately determine C19orf12 protein localization?

To accurately study C19orf12 subcellular localization, researchers should employ multiple complementary techniques:

• Cell fractionation methodology:

  • Isolate cellular fractions including: crude mitochondria, pure mitochondria, membrane-associated mitochondria (MAM), and ER

  • Perform Western blot analysis using specific C19orf12 antibodies on each fraction

  • Include appropriate markers for each subcellular compartment to confirm fraction purity

• Immunolocalization and confocal microscopy:

  • Generate MYC or GFP-tagged C19orf12 constructs for transfection experiments

  • Perform co-localization studies with organelle-specific markers

  • Include both normal and stress conditions to observe dynamic relocalization

• Considerations for wild-type vs. mutant comparison:

  • Always compare wild-type and mutant proteins in parallel experiments

  • Document differential localization patterns between wild-type and disease-associated mutants

Research has demonstrated that wild-type C19orf12 localizes to mitochondria, ER, and MAM regions under normal conditions, while disease-associated mutants show aberrant localization patterns .

What neurological disorders are associated with C19orf12 mutations?

Mutations in C19orf12 are primarily associated with Neurodegeneration with Brain Iron Accumulation (NBIA), specifically a subtype known as MPAN (Mitochondrial membrane Protein-Associated Neurodegeneration) . The clinical features include:

• Core characteristics:

  • Progressive neurodegeneration

  • Iron accumulation in the basal ganglia

  • Later age of onset compared to other NBIA subtypes (like PKAN)

  • Slower disease progression compared to PKAN

• Common clinical manifestations:

  • Psychiatric signs

  • Optic atrophy

  • Motor axonal neuropathy

  • Histopathological findings: Lewy bodies, tangles, spheroids, and tau pathology

MPAN represents a significant proportion of previously undiagnosed NBIA cases. In one study, 18 out of 23 idiopathic NBIA index cases were found to have mutations in C19orf12 .

What specific mutations in C19orf12 have been identified in patients?

Several pathogenic mutations have been identified in the C19orf12 gene:

The most common mutation is the 11bp deletion (c.204_214del11), which appears to derive from a common founder at least 50-100 generations ago based on haplotype analysis .

How does oxidative stress affect C19orf12 protein behavior?

Wild-type and mutant C19orf12 proteins respond differently to oxidative stress conditions:

• Wild-type protein response:

  • Upon induction of oxidative stress, wild-type C19orf12 protein relocates from its normal distribution (mitochondria/ER/MAM) to the cytosol

  • The protein forms distinctive aggregates in the cytoplasm

  • Some of these aggregates partially co-localize with mitochondria

  • This relocation appears to be a functional response to cellular stress

• Mutant protein response:

  • Mutant C19orf12 proteins (including G58S and Q96P variants) are unable to respond appropriately to oxidative stress

  • They do not relocate or form aggregates under stress conditions

  • This failure to respond may contribute to disease pathogenesis

Methodological approach for studying this phenomenon:

• Transfect cells with GFP-tagged wild-type or mutant C19orf12 constructs

• Induce oxidative stress (e.g., with H₂O₂)

• Monitor protein localization using live-cell imaging or fixed-cell confocal microscopy

• Compare wild-type and mutant protein behaviors under identical conditions

What is the relationship between C19orf12 and autophagy?

Recent research suggests C19orf12 may play a role in regulating autophagy:

• Experimental evidence:

  • Overexpression of wild-type C19orf12 results in conversion of the autophagic marker LC3

  • Wild-type C19orf12 overexpression reduces levels of p62 (an autophagy substrate)

  • Delocalization of C19orf12 by oxidative stress results in reduction of LC3 conversion

  • Mutant C19orf12 proteins fail to promote autophagy induction

• Mechanistic hypothesis:

  • The presence of C19orf12 at ER-mitochondria contact sites (MAM) may be significant

  • These contact sites have been shown to be important in autophagosome formation

  • C19orf12 may function in signaling pathways that regulate autophagy initiation or progression

To investigate this connection, researchers should consider:

• Monitoring autophagy markers (LC3-I to LC3-II conversion, p62 levels) in cells with manipulated C19orf12 expression

• Examining autophagosome formation using fluorescent markers

• Comparing autophagy responses in cells expressing wild-type versus mutant C19orf12

How do glycine zipper motifs contribute to C19orf12 function?

The glycine zipper motifs in C19orf12 play crucial roles in protein structure and function:

• Structural importance:

  • Glycine zipper motifs (typically GxxxGxxxG) are common in membrane proteins

  • These motifs are statistically overrepresented in transmembrane domains

  • They facilitate right-handed packing of neighboring helices

  • In C19orf12, they likely mediate interactions between transmembrane helices or homo-dimerization

• Impact of mutations:

  • Mutations that replace glycines with charged or polar residues (as seen in NBIA patients) impair correct membrane localization

  • The G58S mutation causes the protein to mislocalize to the mitochondrial matrix rather than remaining membrane-bound

  • This mislocalization likely disrupts normal protein function

Experimental approaches to study these motifs:

• Site-directed mutagenesis of specific glycine residues

• Membrane insertion assays

• Protein-protein interaction studies (e.g., co-immunoprecipitation)

• Structural analysis of transmembrane domains

How might understanding C19orf12 function inform therapeutic approaches for NBIA?

Research on C19orf12 suggests several potential therapeutic approaches for NBIA:

• Targeting oxidative stress:

  • C19orf12 mutant fibroblasts show increased H₂O₂-induced apoptosis

  • Antioxidant therapies might help mitigate cellular damage

  • Compounds that reduce oxidative stress could be evaluated in patient-derived cells

• Magnesium supplementation:

  • The structural similarity between C19orf12 and bacterial MgtE transporters suggests a possible role in magnesium regulation

  • Magnesium deficiency has been implicated in Parkinson's and other neurodegenerative diseases

  • Studies evaluating magnesium supplementation might be warranted

• Autophagy modulation:

  • If C19orf12 mutations impair autophagy, therapies that enhance this process might be beneficial

  • Autophagy enhancers could potentially compensate for defective C19orf12 function

• Protein mislocalization correction:

  • Approaches that correct protein trafficking or overcome membrane insertion defects could restore normal C19orf12 function

  • Small molecules that stabilize membrane insertion of mutant proteins might be explored

Methodological considerations for therapeutic investigations:

• Use patient-derived fibroblasts or iPSC-derived neurons as disease models

• Employ high-throughput screening to identify compounds that rescue cellular phenotypes

• Develop animal models expressing C19orf12 mutations to test therapeutic approaches in vivo

What are the crucial unanswered questions about C19orf12 protein?

Several important questions remain to be addressed in future C19orf12 research:

• Precise molecular function:

  • What is the exact biochemical function of C19orf12?

  • Does it act as a transporter, a regulator of other proteins, or have enzymatic activity?

  • How does it contribute to lipid metabolism as previously suggested?

• Interaction partners:

  • What proteins does C19orf12 interact with under normal and stress conditions?

  • Does it form complexes with magnesium transporters or other membrane proteins?

  • How do these interactions change in disease states?

• Role at MAM regions:

  • What specific function does C19orf12 serve at ER-mitochondria contact sites?

  • How does it contribute to calcium or lipid transfer between these organelles?

  • What signaling pathways is it involved in at these locations?

• Tissue-specific effects:

  • Why do C19orf12 mutations primarily affect the brain despite its expression in other tissues?

  • What makes neurons particularly vulnerable to C19orf12 dysfunction?

  • Are there tissue-specific interaction partners or regulatory mechanisms?

Methodological approaches to address these questions:

• Proteomics to identify interaction partners

• CRISPR/Cas9 gene editing to create cellular and animal models

• Advanced imaging techniques to study dynamics at membrane contact sites

• Tissue-specific conditional knockout models to assess organ-specific effects

By addressing these questions, researchers may gain critical insights into the pathogenesis of NBIA and potentially identify novel therapeutic targets.